Thermodilution cardiac output measurement during simultaneous volume infusion through the venous infusion port of the pulmonary artery catheter.

Objective: To determine the effect on thermodilution cardiac output (TDCO) measurements of continuous volume infusion through the right atrial venous infusion port of the pulmonary artery catheter.

Design: Prospective, blinded, randomly allocated crossover.

Setting: Surgical intensive care unit in a university hospital.

A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group.

Objective: To evaluate the safety and efficacy of E5, a murine, monoclonal antibody directed against endotoxin, in the treatment of patients with Gram-negative sepsis.

Design: A multicenter, randomized, double-blind, placebo-controlled trial.

Setting: Fifty-three hospitals across the United States, including university medical centers, Veterans Affairs Medical Centers, and community hospitals.

Assessment of critical care nurses' knowledge of the pulmonary artery catheter. The Pulmonary Artery Catheter Study Group.

Objectives: To assess the knowledge and understanding of the use of the pulmonary artery catheter and interpretation of data derived from it in a group of nurses attending the American Association of Critical Care Nurses' National Teaching Institute conference.

Design: A 37-question multiple choice examination that tested knowledge regarding the use of the pulmonary artery catheter was administered to a group of nurses, attending a national conference, who preregistered for a hemodynamics workshop.

Setting: American Association of Critical Care Nurses' National Teaching Institute Conference, New Orleans, LA, May 1992.

Effects of acid-base correction on hemodynamics, oxygen dynamics, and resuscitability in severe canine hemorrhagic shock.

Objective: To compare the effects of hypertonic saline, sodium bicarbonate, and Carbicarb resuscitation on acid-base balance, hemodynamics, and oxygen dynamics in a reperfused, canine hemorrhagic shock model.

Design: Prospective, randomized trial.

Setting: Laboratory at a university medical center.

Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group.

Objective: To further define the safety and efficacy of recombinant human interleukin 1 receptor antagonist (rhIL-1ra) in the treatment of sepsis syndrome.

Study Design: Randomized, double-blind, placebo-controlled, multicenter, multinational clinical trial.

Population: A total of 893 patients with sepsis syndrome received an intravenous loading dose of rhIL-1ra, 100 mg, or placebo followed by a continuous 72-hour intravenous infusion of rhIL-1ra (1.